Poor
Misaligned
Patient Risk:
Moderate
Summary
Several extracted claims are not supported by the provided FDA label excerpts (notably blood sugar increase; adverse-effect-driven dose reduction to 5–10 mg). Some other claims use time-course/decision criteria (3–6 month monitoring; titration-to-40 mg for non-response) that are not explicitly stated in the cited label sections, creating material misalignment with label specificity.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin that inhibits cholesterol production in the liver.
12.1
Lipitor lowers LDL cholesterol.
12.1; 2.1
Lipitor is typically started at a dose of 10–20 mg once daily.
2.1
Lipitor may cause muscle pain as a side effect.
5.1 (muscle aches or muscle weakness/myopathy; advises reporting unexplained muscle pain/tenderness/weakness)
Lipitor may cause liver damage as a side effect.
5.2 (liver dysfunction/transaminase elevations); 6.2 (hepatic failure)
Lipitor typically starts working within 2–4 weeks of starting treatment.
2.1 (lipid levels should be analyzed within 2 to 4 weeks after initiation and/or titration)
Unsupported Statements
Patients who experience adverse effects may need a dose reduction to 5–10 mg once daily.
Not supported in the provided label excerpts; 2.1 provides a dosage range of 10 to 80 mg once daily and guidance to individualize/adjust based on response, but does not state adverse-effect-driven reduction to 5–10 mg.
Cholesterol levels should be checked every 3–6 months while taking Lipitor.
The provided label excerpts specify checking/analyzing lipid levels within 2–4 weeks after initiation/titration (2.1) and recommend periodic testing with a fasting lipid panel (17), but do not specify a 3–6 month interval.
Lipitor may increase blood sugar levels as a side effect.
No blood glucose/blood sugar increase is mentioned in the provided label excerpts.
Contradictions
Low
AI Statement
Patients who do not respond to the initial Lipitor dose may require a dose increase to 40 mg once daily.
Label Reference
2.1
Important Omissions
Label-supported monitoring and adjustment details are incomplete/mischaracterized in the claims: specifically, label states lipid analysis within 2–4 weeks after initiation/titration (2.1) and provides liver function test timing (prior to and at 12 weeks after initiation and after dose increases; periodically thereafter) (5.2). The extracted claims omit these label-specified intervals and instead assert a 3–6 month lipid monitoring frequency.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/incorrect safety-related claim (blood sugar increase) and incorrect/overly specific monitoring interval (3–6 months) could lead to inaccurate risk communication or monitoring expectations. Dose-adjustment guidance (adverse-effect-driven reduction to 5–10 mg) is not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Misaligned
Primary Issue
Multiple extracted claims are not supported by the provided FDA label excerpts (blood sugar increase; adverse-effect-driven reduction to 5–10 mg; explicit 3–6 month monitoring interval) and one dose-increase claim is framed as response-driven titration to 40 mg without explicit label support.
Suggested Improvement
Remove or rephrase unsupported claims. Replace the 3–6 month monitoring interval with label-supported language (lipid analysis within 2–4 weeks after initiation/titration; periodic fasting lipid panel testing). Remove blood sugar increase unless supported by the provided label excerpts. Ensure dose adjustment statements reflect label-supported dosing range and individualized titration/starting-dose guidance (including the condition for initiating at 40 mg).